THEMIS MEDICARE LTD. Q1 FY27 Results

Consolidated PAT for Q1 FY27 was ₹24.61 Cr (EPS ₹2.67 basic) against a ₹14.22 Cr loss in Q1 FY26 — a reported turnaround, but the entire swing owes to a ₹92.95 Cr exceptional gain booked on the sale of 24.97 lakh shares in associate Gujarat Themis Biosyn Ltd for ₹100 Cr consideration (approved by the board on 13 Feb 2026 and shareholders on 27 Mar 2026). Strip that one-off out and the underlying business posted an adjusted net loss of roughly ₹68 Cr, deeper than the ₹14.22 Cr loss a year ago — so this is not a turnaround on an adjusted basis, it is a widening core loss dressed up by an asset sale. Standalone PAT was ₹28.74 Cr (EPS ₹3.12); consolidated is the primary read.

Revenue from operations fell 10.9% YoY to ₹86.96 Cr (₹97.58 Cr in Q1 FY26) while total expenses rose 28.6% YoY to ₹144.90 Cr (₹112.68 Cr), pushing the core pretax loss (before exceptional items and associate income) to ₹56.95 Cr from ₹13.93 Cr — roughly 4x wider. The expense growth was concentrated in purchases of stock-in-trade, up 129.8% YoY to ₹49.81 Cr, and other expenses, up 94.7% to ₹59.21 Cr, even as employee costs fell 10.7% to ₹22.18 Cr. The filing's notes do not explain the jump in trading purchases and other expenses, so the driver behind the cost spike is not disclosed here.

The stock went into the print at ₹103.8, down 10.5% over the past month of trading.

For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 3 consecutive quarters.

Company Secretary transition — Nagraj Mogaveera resigned (moving to Deputy Manager–Secretarial), Suresh Savaliya (ex-Reliance Industries, 23 yrs experience) appointed w.e.f. 13 Aug 2026 — governance change, no P&L impact.

RBI/FEMA approval still pending for a ₹1.29 Cr write-off (₹128.63 lakh receivables + ₹0.76 lakh investment) tied to struck-off UK subsidiary Carpo Medicals; auditors' conclusion is not modified on this matter.

No management press release or MD&A accompanies this filing, and the notes attribute the exceptional gain solely to the Gujarat Themis Biosyn stake sale with no further commentary on the core business. There is no prior management guidance on record, and no analyst/street consensus was found for this print (Themis Medicare carries no visible dedicated brokerage coverage) — both vsGuidance and vsStreet are unknown. Standalone and consolidated PAT diverge by about 17% (₹28.74 Cr vs ₹24.61 Cr): standalone books the full ₹99.67 Cr stake-sale gain while consolidated additionally includes ₹2.59 Cr of share of associate/JV profit. The quarter also saw a Company Secretary transition (Nagraj Mogaveera resigned, Suresh Savaliya appointed w.e.f. 13 Aug 2026) and a series of promoter share-pledge/release/encumbrance disclosures between 21 Jul and 5 Aug 2026 — none of which bear directly on the P&L.